Cour Pharmaceuticals
VerifiedDeveloping nanoparticle technology to help reset the immune system of multiple sclerosis (MS) patients.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$420—630m (Dealroom.co estimates Jan 2024.)
New York City New York (HQ)
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| investor investor investor investor investor investor investor | $0.0 | round | |
* | N/A | Debt | |
| Total Funding | 000k | ||
Related Content
Recent News about Cour Pharmaceuticals
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.